Compare FKWL & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | FKWL | BOLD |
|---|---|---|
| Founded | 1981 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | |
| Sector | Utilities | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.3M | 36.5M |
| IPO Year | 1997 | 2024 |
| Metric | FKWL | BOLD |
|---|---|---|
| Price | $2.94 | $1.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $6.00 | $4.00 |
| AVG Volume (30 Days) | 39.7K | ★ 127.7K |
| Earning Date | 05-15-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.10% | N/A |
| EPS Growth | ★ 94.12 | 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $46,086,901.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.14 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 49.65 | N/A |
| 52 Week Low | $2.88 | $0.96 |
| 52 Week High | $5.48 | $1.68 |
| Indicator | FKWL | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 34.43 | 50.05 |
| Support Level | N/A | $1.40 |
| Resistance Level | $4.42 | $1.55 |
| Average True Range (ATR) | 0.14 | 0.08 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 23.62 | 34.15 |
Franklin Wireless Corp is a provider of wireless solutions, including mobile hotspots, routers, and modems, as well as hardware and software products that support machine-to-machine (M2M) applications and the Internet of Things (IoT). Its M2M and IoT solutions include embedded modules, modems, and gateways built to deliver reliable always-on connectivity supporting a spectrum of applications. These products are designed to solve wireless connectivity challenges in a range of vertical markets, including video surveillance, digital signage, home security, oil and gas exploration, kiosks, fleet management, smart grid, vehicle diagnostics, and telematics.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.